Integrated molecular characterization of IDH-mutant glioblastomas

Area of Science:

• Neuro-oncology
• Molecular Pathology
• Genomics

Background:

• Isocitrate dehydrogenase (IDH)1/2 mutations are prevalent in WHO grade II and III astrocytomas.
• A subset of IDH-mutant astrocytic tumors can progress to or present as IDH-mutant glioblastoma.
• Understanding the molecular landscape of IDH-mutant glioblastomas is crucial for diagnosis and treatment.

Purpose of the Study:

• To investigate the molecular spectrum of IDH-mutant glioblastomas.
• To compare molecular profiles of 'de novo' and 'evolved' IDH-mutant glioblastomas.
• To identify molecular markers associated with prognosis in IDH-mutant glioblastomas.

Main Methods:

• Integrated molecular analysis of 97 IDH-mutant glioblastomas.
• Genome-wide DNA methylation analysis.
• Copy-number profiling and targeted next-generation sequencing using a neurooncology gene panel.

Main Results:

• IDH-mutant glioblastomas, both 'de novo' (68 cases) and 'evolved' (29 cases), formed a distinct molecular group based on DNA methylation.
• This IDH-mutant glioblastoma group was separate from other diffuse glioma subtypes.
• Homozygous deletions of CDKN2A/B were significantly associated with shorter patient survival.

Conclusions:

• IDH-mutant glioblastomas exhibit distinct DNA methylation patterns compared to lower-grade astrocytomas.
• These methylation patterns are homogeneous within both 'de novo' and 'evolved' IDH-mutant glioblastomas.
• CDKN2A alterations may serve as a marker for genetic sub-stratification and prognostic assessment.